The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
The FDA NDA Review Timeline Explained: A Step-by-Step Breakdown
Read More
post
Project Orbis: Accelerating Global Access to Innovative Cancer Therapies
Read More
post
The Importance of Quality in Drug Development with Insights from the FDA Fiscal Year 2023 Report on the State of Pharmaceutical Quality
Read More
post
Why are Biologics Drugs Different
Read More
Let's move from science to success.
Let’s Talk